Generic placeholder image

Current Drug Therapy

Author(s): Navdeep Gahlawat, Ravinder Verma and Deepak Kaushik *

DOI: 10.2174/1574885515666200212094039

DownloadDownload PDF Flyer Cite As
Application of D-optimal Mixture Design for Development and Optimization of Olmesartan Medoxomil Loaded SMEDDS

Page: [548 - 560] Pages: 13

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Olmesartan medoxomil is an angiotensin II receptor blocker antihypertensive drug, which has low oral bioavailability because of poor aqueous solubility.

Objective: The objective of the present research is the development and optimization of Olmesartan medoxomil loaded self-micro emulsifying drug delivery system by D-optimal mixture design to improve its dissolution rate.

Methods: Solubility of Olmesartan medoxomil was determined in different oils, surfactants and cosurfactants. The pseudo ternary diagram was constructed for the identification of self-micro emulsification region. The D-optimal mixture design was employed for the optimization of SMEDDS formulations wherein the factors optimized were the concentration of oil (X1), surfactant (X2), and co-surfactant (X3) and the response was globule size (Y1) and dissolution rate (Y2). Developed selfmicroemulsifying drug delivery system was further assessed for self-emulsification time, drug loading capacity, transparency, globule size, in vitro dissolution and comparative in vitro dissolution testing of optimized formulation with pure medicament and commercially available product.

Results: The application of D-optimal mixture design resulted in 14 batches out of which F-5 was found to be the optimized batch which contained Olmesartan medoxomil (20 mg), Capmul MCM EP (23% v/v), Kolliphore EL (49% v/v) and Transcutol P (28% v/v) having globule size of 105 nm, 94.7% dissolution within 30 minutes. In vitro dissolution rate of the drug from SMEDDS was appreciably higher than that of pure drug and marketed products.

Conclusion: Olmesartan medoxomil self-microemulsifying drug delivery system was successfully developed and this approach could prove to be suitable for the improvement of the dissolution rate of BCS II class drugs.

Keywords: Bioavailability, D-optimal mixture design, SMEDDS, in vitro lipolysis, in vitro dissolution, Fasted State Stimulated Intestinal Fluids Media (FaSSIF).

Graphical Abstract

[1]
Padia N, Shukla AK, Shelat P. Development and characterization of telmisartan self-microemulsifying drug delivery system for bioavailability enhancement. J Sci Ind Res 2015; 4(3): 153-64.
[2]
Kim DS, Cho JH, Park JH, et al. Self-microemulsifying Drug Delivery System (SMEDDS) for improved oral delivery and photostability of methotrexate. Int J Nanomedicine 2019; 14: 4949-60.
[http://dx.doi.org/10.2147/IJN.S211014] [PMID: 31308665]
[3]
Verma R, Mittal V, Kaushik D. Self-micro emulsifying medicament delivery system: a vital approach for bioavailability enhancement. Int J Chemtech Res 2017; 10(17): 515-28.
[4]
Bharti D, Pandey P, Verma R, Kaushik D. Development and characterization of rosuvastatin loaded self-emulsifying drug delivery system. Appl Clin Res Clin Trials Regul Aff 2018; 5: 1-8.
[http://dx.doi.org/10.2174/2213476X05666180309160113]
[5]
Verma R, Mittal V, Kaushik D. Quality based design approach for improving oral bioavailability of valsartan loaded SMEDDS and study of impact of lipolysis on the drug diffusion. Drug Deliv Lett 2018; 8(2): 130-9.
[http://dx.doi.org/10.2174/2210303108666180313141956]
[6]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71-104.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[7]
Mottaghitalab F, Farokhi M, Shokrgozar MA, Atyabi F, Hosseinkhani H. Silk fibroin nanoparticle as a novel drug delivery system. J Control Release 2015; 206: 161-76.
[http://dx.doi.org/10.1016/j.jconrel.2015.03.020] [PMID: 25797561]
[8]
Hosseinkhani H, Chen YR, He WJ, Hong PD, Yu DS, Domb AJ. Engineering of magnetic DNA nanoparticles for tumor-targeted therapy. J Nanopart Res 2013; 15: 1345-56.
[http://dx.doi.org/10.1007/s11051-012-1345-z]
[9]
He WJ, Hosseinkhani H, Hong PD, Chiang CH, Yu DS. Magnetic nanoparticles for imaging technology. Int J Nanotechnol 2013; 10: 930-44.
[http://dx.doi.org/10.1504/IJNT.2013.058120]
[10]
Abedini F, Ebrahimi M, Roozbehani AH, Domb AJ, Hosseinkhani H. Overview on natural hydrophilic polysaccharide polymers in drug delivery. Polym Adv Technol 2018; 29: 2564-73.
[http://dx.doi.org/10.1002/pat.4375]
[11]
Wadhwa J, Nair A, Kumri R. Selfemulsifying therapeutic system: a potential approach for delivery of lipophilic drugs. Braz J Pharm Sci 2011; 47(3): 1-16.
[http://dx.doi.org/10.1590/S1984-82502011000300003]
[12]
Anand S, Gupta R. Self-microemulsifying drug delivery system: a review. World J Pharm Pharm Sci 2016; 4(8): 506-22.
[13]
Thakare P, Mogal V, Borase P, Dusane J, Kshirsagar A. A review on self-emulsifying drug delivery system. Pharmaceutical and Bio Evalu 2016; 3(2): 140-53.
[14]
Paresh K, Patel MR, Patel KR. Design and development of self-microemulsifying drug delivery system of febuxostat. J Int Universal Pharmacy Bio Sci 2014; 3(2): 2212-31.
[15]
Chaus HA, Chopade VV, Chaudhri PD. Self-emulsifying drug delivery system: a review. Int J Pharm Chem Sci 2013; 2: 34-44.
[16]
Pandya BD, Shah SH, Shah N. Bioavailability enhancement of poorly water soluble drugs by SMEDDS: A review. Int J Pharm Sci Res 2015; 5: 187-06.
[17]
Brahmaiah BK, Sasikanth A, Nama S, Suresh P, Khan PA. Formulation and dissolution study of telmisartan immediate release tablets. Int J Innovative Drug Disc 2013; 3(1): 33-8.
[18]
Oh DH, Kang JH, Kim DW, et al. Comparison of solid self-microemulsifying drug delivery system (solid SMEDDS) prepared with hydrophilic and hydrophobic solid carrier. Int J Pharm 2011; 420(2): 412-8.
[http://dx.doi.org/10.1016/j.ijpharm.2011.09.007] [PMID: 21944892]
[19]
Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004; 58(3): 173-82.
[http://dx.doi.org/10.1016/j.biopha.2004.02.001] [PMID: 15082340]
[20]
Date AA, Nagarsenker MS. Design and evaluation of Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm 2007; 329(1-2): 166-72.
[http://dx.doi.org/10.1016/j.ijpharm.2006.08.038] [PMID: 17010543]
[21]
Patel JB, Patel MR. Self-micro emulsifying drug delivery system: a review. World Int J Pharma Pharm Sci 2016; 5(4): 2215-32.
[22]
Potphode VR, Deshmukh AS, Mahajan VR. Self-micro emulsifying drug delivery system: an approach for enhancement of bioavailability of poorly water soluble drugs. Asian J Pharm Sci 2016; 6(3): 159-68.
[http://dx.doi.org/10.5958/2231-5713.2016.00023.4]
[23]
Hyma P. Formulation and characterization of novel self-micro emulsifying drug delivery system of glimepiride. Experiment 2014; 24(1): 1640-8.
[24]
Lee DR, Ho MJ, Jung HJ, et al. Enhanced dissolution and oral absorption of tacrolimus by supersaturable self-emulsifying drug delivery system. Int J Nanomedicine 2016; 11: 1109-17.
[PMID: 27051286]
[25]
Lee JH, Kim HH, Cho YH, Koo TS, Lee GW. Development and evaluation of raloxifene-hydrochloride-loaded supersaturatable SMEDDS containing an acidifier. Pharmaceutics 2018; 10(3): 78-88.
[http://dx.doi.org/10.3390/pharmaceutics10030078] [PMID: 29966249]
[26]
Kim HJ, Yoon KA, Hahn M, Park ES, Chi SC. Preparation and in vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. Drug Dev Ind Pharm 2000; 26(5): 523-9.
[http://dx.doi.org/10.1081/DDC-100101263] [PMID: 10789064]
[27]
Midha K, Nagpal M, Aggarwal G, Singh TG. Development of dispersible self-microemulsifying tablet of atorvastatin. Pharm Methods 2015; 6(1): 9-26.
[http://dx.doi.org/10.5530/phm.2015.6.2]
[28]
Thakkar H. nagesh J, Parmar M, Patel D. Formulation and characterization of lipid based drug delivery system of raloxifene microemulsion and selfmicroemulsifying drug delivery system. J Pharm Bioallied Sci 2011; 3(3): 442-8.
[http://dx.doi.org/10.4103/0975-7406.84463] [PMID: 21966167]
[29]
Mosgaard MD, Sassene P, Mu H, Rades T, Müllertz A. Development of a high-throughput in vitro intestinal lipolysis model for rapid screening of lipid-based drug delivery systems. Eur J Pharm Biopharm 2015; 94: 493-500.
[http://dx.doi.org/10.1016/j.ejpb.2015.06.028] [PMID: 26159837]
[30]
Xiao L, Yi T, Liu Y, Zhou H. The in vitro lipolysis of lipid-based drug delivery systems: a newly identified relationship between drug release and liquid crystalline phase. BioMed Res Int 2016; 20162364317
[http://dx.doi.org/10.1155/2016/2364317] [PMID: 27294110]
[31]
Sassene P, Karen K, Williams HD, Mullertz A. Toward establishment of standardized in vitro tests for LBDs, Part 6: Effect of varying pancreatin and calcium levels. AAPS J 2014; 16(6): 1344-57.
[http://dx.doi.org/10.1208/s12248-014-9672-x] [PMID: 25274609]
[32]
Patel D, Sawant KK. Self micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. Curr Drug Deliv 2009; 6(4): 419-24.
[http://dx.doi.org/10.2174/156720109789000519] [PMID: 19534704]
[33]
Williams HD, Anby MU, Sassene P, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. Mol Pharm 2012; 9(11): 3286-300.
[http://dx.doi.org/10.1021/mp300331z] [PMID: 23030411]